Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Jumping Again Today

By Keith Speights – Sep 1, 2021 at 12:10PM

Key Points

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors like that the vaccine maker will soon begin an additional clinical trial targeting the delta variant.

What happened

Shares of Novavax (NVAX -1.96%) were jumping 8.2% as of 11:58 a.m. EDT on Wednesday. This gain appears to be related to news that the company will soon initiate a phase 1/2 clinical study evaluating three COVID-19 vaccine constructs that use the Matrix-M1 adjuvant in targeting the coronavirus beta and delta variants.

So what

Novavax didn't issue a press release announcing the planned clinical study targeting coronavirus variants. Instead, details about the study were posted on the National Institute of Health's ClinicalTrials.gov website. 

A healthcare professional giving a shot in the arm of a person.

Image source: Getty Images.

The phase 1/2 study is scheduled to begin on Oct. 4, 2021, and continue through June 2022. Novavax expects to enroll 240 participants. The company will evaluate one vaccine candidate targeting the beta variant, another candidate targeting the ancestral coronavirus strain and the beta variant, and a third candidate targeting the delta variant.

Investors appear to be pleased that Novavax is making progress with its efforts to focus on the delta variant in particular. 

Now what

While this planned clinical trial is good news for Novavax, the major catalysts for the vaccine stock are still on the way. Novavax plans to file for Emergency Use Authorization (EUA) in the U.K. by the end of this month and in the U.S. in the fourth quarter of 2021. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Novavax Stock Quote
Novavax
NVAX
$16.52 (-1.96%) $0.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.